| Description | BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl. |
| Synonyms | 2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1,3-dioxoisoindoline-5-carboxylic acid |
| molecular weight | 377.35 |
| Molecular formula | C20H15N3O5 |
| CAS | 292870-53-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 10 mg/mL (26.5 mM), Sonication and heating to 80℃ are recommended. |
| References | 1. Mancini M, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther. 2011 Mar;336(3):596-604. 2. Valensin D, et al. Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions. Bioorg Med Chem Lett. 2016 Feb 1;26(3):894-898. |